• 1
    Thwin M.M., Ong W.Y., Fong C.W., Sato K., Kodama K., Farooqui A.A., Gopalakrishnakone P. (2003) Secretory phospholipase A2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. Exp Brain Res;150:427433.
  • 2
    Farooqui A.A., Ong W.Y., Horrocks L.A., Farooqui T. (2000) Brain cytosolic phospholipase A2: localization, role, and involvement in neurological diseases. Neuroscientist;6:169180.
  • 3
    Farooqui A.A., Litsky M.L., Farooqui T., Horrocks L.A. (1999) Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders – from molecular biology to therapy. Brain Res Bull;49:139153.
  • 4
    Six D.A., Dennis E.A. (2000) The expanding super family of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta;1488:119.
  • 5
    John E.B., Dennis E.A. (2009) Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res;50:237242.
  • 6
    Zheng L.T., Ryu G.M., Kwon B.M., Lee W.H., Suk K. (2008) Anti-inflammatory effects of catechols in lipopolysaccharide-stimulated microglia cells: inhibition of microglial neurotoxicity. Eur J Pharmacol;588:106113.
  • 7
    Miranda J.L., Patricia J.E., Michele A.M., Hoult J.R.S., Barry H. (1991) Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives: relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol;42:16731681.
  • 8
    da Silva S.L., Calgarotto A.K., Maso V., Damico D.C.S., Baldasso P., Veber C.L., Villar J.A.F.P., Oliveira A.R.M., Comar M. Jr, Oliveira K.M.T., Marangoni S. (2009) Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds. Eur J Med Chem;44:312321.
  • 9
    Leslie A.G.W. (2006) The integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr;62:4857.
  • 10
    Vagin A., Teplyakov A. (2000) An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr;56:16221624.
  • 11
    Murshudov G.N., Vagin A.A., Dodson E.J. (1997) Refinement of macromolecular structures by the maximum likelihood method. Acta Crystallogr D Biol Crystallogr;53:240255.
  • 12
    Emsley P., Cowtan K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr;60:21262132.
  • 13
    Lee M.S., Olson M.A. (2006) Calculation of absolute protein-ligand binding affinity using path and endpoint approaches. Biophys J;90:864877.
  • 14
    Guex N., Peitsch M.C. (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis;18:27142723.
  • 15
    Kaushik S., Prem Kumar R., Sinha M., Kaur P., Sharma S., Singh T.P. Crystal structure of the complex of group I phospholipase A2 with 4-Methoxy-benzoic acid at 1.4 A resolution. PDB; doi:10.2210/pdb3nju/pdb.
  • 16
    Fernandes C.A., Marchi-Salvador D.P., Salvador G.M., Silva M.C., Costa T.R., Soares A.M., Fontes M.R. (2010) Comparison between apo and complexed structures of bothropstoxin-I reveals the role of Lys122 and Ca(2+)-binding loop region for the catalytically inactive Lys49-PLA(2)s. J Struct Biol;171:3143.
  • 17
    Kumar S., Vikram G., Singh N., Sinha M., Sharma S., Kaur P., Srinivasan A., Singh T.P. Crystal structure of the complex of group II phospholipase A2 with Eugenol. PDB; doi:10.2210/pdb2qu9/pdb.
  • 18
    Singh N., Jabeen T., Sharma S., Bhushan A., Singh T.P. Crystal structure of a complex formed between group II phospholipase A2 and aspirin at 1.86 A resolution. PDB; doi:10.2210/pdb1tgm/pdb.